MOLINA® HEALTHCARE

Gout Agents

Please provide the information below, please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. **Please FAX responses to: (800) 869-7791. Phone: (855) 322-4082.**

Date of request:			
Patient	Date of birth	Molina ID	
Pharmacy name	Pharmacy NPI	Telephone number	Fax number
Prescriber	Prescriber NPI	Telephone number	Fax number
Medication and strength		Directions for use	Qty/Days supply

1. Is this request for a continuation of existing therapy? ☐ Yes ☐ No
   If yes, is there documentation showing a positive clinical response? ☐ Yes ☐ No
2. Please indicate patient's diagnosis:
   - ☐ Symptomatic hyperuricemia associated with gout
   - ☐ Other. Specify: _____

For febuxostat (Uloric) and pegloticase (Krystexxa), answer the following:

3. Has patient's diagnosis been confirmed by one of the following:
   - ☐ Measurement of blood uric acid levels
   - ☐ Measurement of erythrocyte sedimentation rate
   - ☐ Polarized light microscopy for identification of crystal in synovial fluids obtained from joints or bursas
   - ☐ Magnetic resonance imaging for gouty tophus
4. Has patient had any of the following in the last 18 months?
   - ☐ At least 3 gout flares that were inadequately controlled by colchicine, corticosteroids, or non-steroidal anti-inflammatory drugs (NSAIDs)
   - ☐ At least 1 gout tophus or gouty arthritis
5. Have medications known to precipitate gout attacks been discontinued/changed?
   ☐ Yes ☐ No
   If no, explain: _____

For pegloticase (Krystexxa), answer the following:

6. Does patient have a history of failure (normalize serum uric acid to less than 6 mg/dL) to at least 3 months at maximum tolerated dose, contraindication or intolerance to allopurinol AND febuxostat? ☐ Yes ☐ No
7. Does the patient have history of G6PD deficiency? ☐ Yes ☐ No
8. Will the patient take an oral urate-lowering medication while on Krystexxa? ☐ Yes ☐ No

For febuxostat (Uloric), answer the following:

BLACK BOX WARNING:

- **Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcome study.**
- **Consider the risks and benefits of febuxostat when deciding to prescribe or continue patients on febuxostat. Febuxostat should only be used in patients who have inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.**

9. Does patient have a history of failure (normalize serum uric acid to less than 6 mg/dL) to at least 3 months at maximum tolerated dose, contraindication or intolerance to allopurinol? ☐ Yes ☐ No
10. Will the patient be taking azathioprine or mercaptopurine? ☐ Yes ☐ No
11. Has prescriber assessed cardiovascular risk factors to determine the benefits and risk associated with febuxostat and counseled the patient about the cardiovascular risks with febuxostat? ☐ Yes ☐ No

CHART NOTES ARE REQUIRED WITH THIS REQUEST

Prescriber signature	Prescriber specialty	Date

MOLINA® HEALTHCARE